600226.SHG Zhejiang Shenghua Biok Biology Co Ltd
- Market cap
- CNY 12.6B
- P/E
- 85.0x
- P/B
- 3.14x
- ROE
- 4.3%
- Dividend yield
- 0.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is 600226.SHG undervalued?
Graham numberThe Graham number of Zhejiang Shenghua Biok Biology Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Shenghua Biok Biology Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Shenghua Biok Biology Co Ltd yet.
Zhejiang Shenghua Biok Biology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Shenghua Biok Biology Co Ltd
Zhejiang Hengtong Holding Co.,Ltd. engages in the research, development, production, and sale of electrolytic copper foil, veterinary drugs, and animal feed additive products in China and internationally. The company offers electronic and lithium battery copper foil for use in integrated circuit boards, lithium battery electrodes, and other products, as well as amino acid products. It also engages in the research, production, and sales of bioveterinary drugs, feed additives,…
Full company profileZhejiang Shenghua Biok Biology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Shenghua Biok Biology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01B | 513M | 1.32B | 982M | 805M | 556M | 681M | 602M | 648M | 1.33B | 3.54B |
| Gross Profit | 120M | 78.8M | 296M | 393M | 220M | 35.5M | 106M | 79.4M | 130M | 150M | 323M |
| Operating Income | 127M | 272M | 295M | 151M | -641M | -935M | 391M | 540M | 175M | 197M | 110M |
| EBITDA | 35.6M | 18.4M | 141M | 128M | -68.7M | -503M | 22.8M | -3.63M | 66.4M | 67.7M | 177M |
| Net Income | 140M | 236M | 261M | 142M | -656M | -942M | 375M | 482M | 166M | 189M | 163M |
| EPS | 0.07 | 0.12 | 0.09 | 0.05 | -0.21 | -0.30 | 0.13 | 0.16 | 0.06 | 0.06 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 2.24B | 3.37B | 5.45B | 5.07B | 4.16B | 3.05B | 2.94B | 3.32B | 4.31B | 4.50B | 6.73B |
| Total Liabilities | 817M | 1.66B | 1.25B | 736M | 619M | 422M | 289M | 230M | 826M | 1.08B | 2.95B |
| Shareholders' Equity | 1.41B | 1.70B | 4.20B | 4.34B | 3.55B | 2.63B | 2.66B | 3.09B | 3.26B | 3.42B | 3.77B |
| Cash & Short-term Investments | 219M | 1.20B | 848M | 472M | 100M | 101M | 429M | 1.00B | 947M | 847M | 691M |
| Total Debt | 452M | 485M | 892M | 432M | 285M | 166M | 5.70M | 12.3M | 315M | 387M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 69.2M | -55.3M | 82.3M | -176M | -78.2M | 46.5M | 105M | 25.2M | -76.7M | -31.3M | - |
| Capital Expenditure | 61.0M | 60.8M | 168M | 161M | 77.2M | 15.2M | 18.9M | 23.8M | 396M | 132M | 550M |
| Free Cash Flow | 8.21M | -116M | -85.3M | -337M | -155M | 31.3M | 86.4M | 1.44M | -473M | -163M | -125M |
| Ratios | |||||||||||
| ROE | 9.9% | 13.9% | 6.2% | 3.3% | -18.5% | -35.8% | 14.1% | 15.6% | 5.1% | 5.5% | 4.3% |
| ROA | 6.3% | 7.0% | 4.8% | 2.8% | -15.8% | -30.9% | 12.7% | 14.5% | 3.8% | 4.2% | 2.4% |
| Net Profit Margin | 13.8% | 45.9% | 19.8% | 14.4% | -81.4% | -169.6% | 55.1% | 80.1% | 25.6% | 14.2% | 4.6% |
| Debt to Equity | 0.32x | 0.29x | 0.21x | 0.10x | 0.08x | 0.06x | 0.00x | 0.00x | 0.10x | 0.11x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Shenghua Biok Biology Co Ltd dividends
- Dividend yield
- 0.11%
- Forward dividend
- -
- Payout ratio
- 7.0%
- Ex-dividend date
- Jul 11, 2019
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | CNY 13.3M | 0.00 | 7.0% |
| 2023 | CNY 5.27M | 0.00 | 3.2% |
| 2022 | CNY 564K | 0.00 | 0.1% |
| 2021 | CNY 2.70M | 0.00 | 0.7% |
| 2020 | CNY 13.1M | 0.00 | - |
| 2019 | CNY 68.5M | 0.02 | - |
| 2018 | CNY 42.5M | 0.01 | 30.0% |
| 2017 | CNY 29.2M | 0.01 | 11.2% |
| 2016 | CNY 29.2M | 0.01 | 12.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Mar 26, 2018.
Who owns Zhejiang Shenghua Biok Biology Co Ltd
- Insiders 43.24%
- Institutions 1.05%
- Public & others 55.71%
- Shares outstanding 2.97B
- Free float 1.72B
Zhejiang Shenghua Biok Biology Co Ltd company profile
- Company name
- Zhejiang Shenghua Biok Biology Co Ltd
- Ticker
- 600226.SHG
- ISIN
- CNE0000010Q7
- Exchange
- Shanghai Stock Exchange
- Listed since
- Aug 20, 1999
- Sector
- Industrials
- Industry
- Chemicals
- Employees
- 1,046
- Fiscal year end
- December
- Address
- Building C15, Huzhou, China, 313200
- Phone
- 86 57 2821 9166
- Website
- zjhtkg.com
About Zhejiang Shenghua Biok Biology Co Ltd
Zhejiang Hengtong Holding Co.,Ltd. engages in the research, development, production, and sale of electrolytic copper foil, veterinary drugs, and animal feed additive products in China and internationally. The company offers electronic and lithium battery copper foil for use in integrated circuit boards, lithium battery electrodes, and other products, as well as amino acid products. It also engages in the research, production, and sales of bioveterinary drugs, feed additives, biopesticides, pharmaceutical intermediates, and food additives; combined heat and power generation and district heating, which includes electricity and steam; films and composite film materials and their products; and investment business. Zhejiang Hengtong Holding Co.,Ltd. was founded in 1993 and is based in Huzhou, China.
Zhejiang Shenghua Biok Biology Co Ltd management
2- Mr. Haijiang LiPresident · born 1971
- Mr. Li Ming LuAccounting Supervisor, Financial Director & Director · born 1974